CASBF (CanSino Biologics) Short-Term Debt: $45.22 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASBF CanSino Biologics Inc CASBF
69 GF Score
Price $2.60
GF Value $8.73
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is CanSino Biologics Short-Term Debt?

CanSino Biologics CASBF 69 Short-Term Debt is $45.22 Mil as of Dec. 2025. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.73 (Significantly Undervalued). The stock has 3 warning signs investors should review.

CanSino Biologics's Short-Term Debt for the quarter that ended in Dec. 2025 was $45.22 Mil.

CanSino Biologics's quarterly Short-Term Debt declined from Jun. 2025 ($140.41 Mil) to Sep. 2025 ($10.28 Mil) but then increased from Sep. 2025 ($10.28 Mil) to Dec. 2025 ($45.22 Mil).

CanSino Biologics's annual Short-Term Debt declined from Dec. 2023 ($195.35 Mil) to Dec. 2024 ($122.54 Mil) and declined from Dec. 2024 ($122.54 Mil) to Dec. 2025 ($45.22 Mil).

CanSino Biologics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CanSino Biologics Short-Term Debt Related Terms

CanSino Biologics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for CanSino Biologics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Short-Term Debt Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 169.69 226.00 195.35 122.54 45.22

CanSino Biologics Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Jun25 Sep25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.34 122.54 140.41 10.28 45.22
CASBF
69GF Score
CanSino Biologics Inc CASBF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $45.22 Mil mean?
CanSino Biologics (CASBF) has a Short-Term Debt of $45.22 Mil as of Dec. 2025.
Is CanSino Biologics' Short-Term Debt too high?
CanSino Biologics' current Short-Term Debt is $45.22 Mil. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Short-Term Debt compare to ZTS and UTHR?
CanSino Biologics' Short-Term Debt of $45.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. CanSino Biologics's current Short-Term Debt is $45.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.73, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Short-Term Debt is $45.22 Mil. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Short-Term Debt is $45.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CanSino Biologics (CASBF) Overvalued in 2026?

Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued. The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.73. GuruFocus considers CanSino Biologics to be Significantly Undervalued.

Key valuation signals for CASBF:

  • Short-Term Debt: $45.22 Mil
  • GF Value™: $8.73 vs. price of $2.60 (70.2% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CanSino Biologics Business Description

Address 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score

Get the complete analysis for CASBF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.60
Price
$8.73
GF Value